605.52
price down icon0.40%   -2.43
after-market Handel nachbörslich: 605.52
loading
Schlusskurs vom Vortag:
$607.95
Offen:
$612.98
24-Stunden-Volumen:
159.99K
Relative Volume:
0.63
Marktkapitalisierung:
$36.93B
Einnahmen:
$2.19B
Nettoeinkommen (Verlust:
$833.04M
KGV:
47.64
EPS:
12.71
Netto-Cashflow:
$-1.28B
1W Leistung:
-0.93%
1M Leistung:
-3.11%
6M Leistung:
+10.29%
1J Leistung:
+51.98%
1-Tages-Spanne:
Value
$597.50
$612.98
1-Wochen-Bereich:
Value
$597.50
$627.00
52-Wochen-Spanne:
Value
$352.77
$678.21

Argen X Se Adr Stock (ARGX) Company Profile

Name
Firmenname
Argen X Se Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
1,639
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
ARGX's Discussions on Twitter

Vergleichen Sie ARGX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ARGX
Argen X Se Adr
605.52 36.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
509.04 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.14 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
280.96 36.37B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
250.47 27.23B 3.81B -644.79M -669.77M -6.24

Argen X Se Adr Stock (ARGX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-17 Hochstufung Bernstein Mkt Perform → Outperform
2025-03-12 Hochstufung Deutsche Bank Sell → Hold
2025-01-17 Herabstufung Deutsche Bank Hold → Sell
2024-11-12 Hochstufung Wolfe Research Peer Perform → Outperform
2024-11-05 Hochstufung Scotiabank Sector Perform → Sector Outperform
2024-11-01 Herabstufung Robert W. Baird Outperform → Neutral
2024-11-01 Hochstufung William Blair Mkt Perform → Outperform
2024-10-10 Fortgesetzt Raymond James Strong Buy
2024-10-04 Herabstufung Deutsche Bank Buy → Hold
2024-08-06 Hochstufung Barclays Equal Weight → Overweight
2024-07-25 Hochstufung Deutsche Bank Hold → Buy
2024-07-23 Hochstufung Oppenheimer Perform → Outperform
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-12-20 Herabstufung Deutsche Bank Buy → Hold
2023-12-20 Herabstufung William Blair Outperform → Mkt Perform
2023-07-31 Eingeleitet Scotiabank Sector Perform
2023-07-24 Herabstufung UBS Buy → Neutral
2023-07-17 Fortgesetzt Evercore ISI Outperform
2023-06-15 Eingeleitet Societe Generale Sell
2023-05-31 Eingeleitet UBS Buy
2023-04-25 Eingeleitet Citigroup Buy
2023-03-14 Hochstufung Robert W. Baird Neutral → Outperform
2022-12-07 Eingeleitet William Blair Outperform
2022-10-12 Eingeleitet Oppenheimer Perform
2022-07-29 Herabstufung Robert W. Baird Outperform → Neutral
2022-06-28 Fortgesetzt Stifel Buy
2022-05-03 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-11-29 Hochstufung Piper Sandler Neutral → Overweight
2021-10-29 Hochstufung Guggenheim Neutral → Buy
2021-10-28 Hochstufung Raymond James Outperform → Strong Buy
2021-10-07 Eingeleitet Jefferies Buy
2021-09-23 Hochstufung Redburn Neutral → Buy
2021-09-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-07-23 Eingeleitet Deutsche Bank Hold
2021-07-19 Fortgesetzt Wolfe Research Outperform
2021-06-18 Eingeleitet UBS Buy
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-05-10 Hochstufung H.C. Wainwright Neutral → Buy
2021-04-23 Eingeleitet Redburn Neutral
2021-03-05 Bestätigt H.C. Wainwright Neutral
2021-02-02 Herabstufung Piper Sandler Overweight → Neutral
2021-01-04 Herabstufung Guggenheim Buy → Neutral
2020-08-25 Eingeleitet Raymond James Outperform
2020-08-19 Herabstufung Evercore ISI Outperform → In-line
2020-07-29 Eingeleitet H.C. Wainwright Neutral
2020-02-10 Eingeleitet BofA/Merrill Buy
2019-11-05 Eingeleitet Credit Suisse Neutral
2019-10-31 Hochstufung William Blair Mkt Perform → Outperform
2019-10-22 Eingeleitet JP Morgan Overweight
2019-09-27 Eingeleitet Wells Fargo Market Perform
2019-09-16 Fortgesetzt Cowen Outperform
2019-06-28 Eingeleitet Robert W. Baird Outperform
2019-01-18 Fortgesetzt SunTrust Buy
2019-01-04 Eingeleitet Morgan Stanley Overweight
2018-12-17 Eingeleitet Goldman Buy
2018-12-14 Eingeleitet Wolfe Research Outperform
2018-06-29 Eingeleitet Nomura Buy
2018-04-09 Eingeleitet SunTrust Buy
2018-01-29 Bestätigt JMP Securities Mkt Outperform
Alle ansehen

Argen X Se Adr Aktie (ARGX) Neueste Nachrichten

pulisher
Mar 17, 2025

Bernstein double upgrades Argenx to "outperform," raises price target to €755 By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 17, 2025

Bernstein double upgrades Argenx to "outperform," raises price target to €755 - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Bernstein raises argenx stock rating, hikes target to EUR755 - Investing.com

Mar 17, 2025
pulisher
Mar 13, 2025

TD Cowen maintains argenx stock with $761 target, bullish outlook - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

TD Cowen maintains argenx stock with $761 target, bullish outlook By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Deutsche Bank lifts argenx stock rating to hold, sets EUR575 target By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 10, 2025

Guggenheim raises argenx stock target to $1,100 on growth outlook - Investing.com India

Mar 10, 2025
pulisher
Mar 07, 2025

argenx SE ADR to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Argenx Publishes Long-Term Data At The American Academy Of Neurology 2025 Annual Meeting - Marketscreener.com

Mar 07, 2025
pulisher
Feb 28, 2025

Argenx Benefits From Multiple Approved Indications of Vyvgart and Strong Uptake - Morningstar

Feb 28, 2025
pulisher
Feb 28, 2025

Argenx's Q4 Sales Backed by Vyvgart's Growth, Oppenheimer Says -February 28, 2025 at 11:05 am EST - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts argenx stock price target to $720 By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts argenx stock price target to $720 - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Argenx stock target raised to $701 by JMP on VYVGART strength - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 27, 2025

Argenx stock target lifted to $761 by TD Cowen, maintains buy - Investing.com India

Feb 27, 2025
pulisher
Feb 27, 2025

Argenx’s VYVGART Franchise Drives Strong Performance and Growth Prospects - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

argenx ADR earnings beat by $10.57, revenue topped estimates - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 27, 2025

Argenx Q4 Swings to Earnings, Operating Income Increases -February 27, 2025 at 04:00 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Immunology Company argenx Swings to Profit in FY24; Net Sales Climb -February 27, 2025 at 01:24 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Argenx: $737 Million In Q4 Global Product Net Sales -February 27, 2025 at 01:14 am EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 19, 2025

Argenx Vaults 3,659% With Profit Growth Seen In Triple Digits; Earnings Next As Stock Hits Highs - Investor's Business Daily

Feb 19, 2025
pulisher
Feb 07, 2025

BBVA Argentina ADR (BBAR) Shares Rise Despite Market Challenges - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Telecom Argentina S.A. ADR (TEO) Stock Records 32.38% Quarterly Movement - The News Heater

Feb 07, 2025
pulisher
Feb 06, 2025

Guru Fundamental Report for ARGXBenjamin Graham - Nasdaq

Feb 06, 2025
pulisher
Feb 03, 2025

Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.

Feb 03, 2025
pulisher
Jan 30, 2025

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Jan 30, 2025
pulisher
Jan 29, 2025

argenx SE : The stock is approaching a major resistance level -January 29, 2025 at 04:11 am EST - Marketscreener.com

Jan 29, 2025
pulisher
Jan 15, 2025

argenx's SWOT analysis: biotech stock soars on VYVGART success, pipeline promise - Investing.com India

Jan 15, 2025
pulisher
Jan 14, 2025

Argenx stock price target raised to $717 by H.C. Wainwright - Investing.com India

Jan 14, 2025
pulisher
Jan 14, 2025

Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance

Jan 14, 2025
pulisher
Jan 13, 2025

Truist Securities raises argenx stock rating to Buy, says will exceed Vision 2030 - Investing.com

Jan 13, 2025
pulisher
Jan 13, 2025

Jefferies raises argenx stock target, reaffirms buy on global sales result - Investing.com

Jan 13, 2025
pulisher
Jan 07, 2025

argenx's SWOT analysis: biotech stock soars on vyvgart success - Investing.com

Jan 07, 2025
pulisher
Jan 07, 2025

Piper Sandler increases argenx stock price target on revised estimates - Investing.com

Jan 07, 2025
pulisher
Jan 06, 2025

Argenx stock soars to all-time high of $645.31 amid robust growth - Investing.com

Jan 06, 2025
pulisher
Dec 28, 2024

Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment - Yahoo Finance

Dec 28, 2024
pulisher
Dec 23, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Dec 23, 2024
pulisher
Dec 16, 2024

Argenx stock soars to all-time high of $630.4 amid robust growth By Investing.com - Investing.com South Africa

Dec 16, 2024
pulisher
Dec 16, 2024

Argenx stock soars to all-time high of $630.4 amid robust growth - Investing.com

Dec 16, 2024
pulisher
Dec 15, 2024

argenx's SWOT analysis: biotech stock soars on VYVGART success - Investing.com

Dec 15, 2024

Finanzdaten der Argen X Se Adr-Aktie (ARGX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$280.96
price down icon 3.35%
biotechnology ONC
$250.47
price down icon 1.08%
$97.05
price down icon 3.57%
$20.24
price down icon 2.17%
$33.76
price up icon 0.03%
Kapitalisierung:     |  Volumen (24h):